Tackling Key Epidemiological And Basic Scientific Research Issues In Prion Diseases.
Funder
National Health and Medical Research Council
Funding Amount
$401,109.00
Summary
Proposed Practitioner Fellowship research will simultaneously include epidemiological and basic scientific projects, emphasising human prion disease. Epidemiological research will involve large-scale studies to clarify genetic factors that influence susceptibility to developing prion disease, as well as clarify whether Alzheimer disease is transmissible, while basic scientific research will include determining the characteristics of the misfolded prion proteins causing neuronal disease.
Prevention And Improved Management Of Paediatric Food Allergy
Funder
National Health and Medical Research Council
Funding Amount
$479,882.00
Summary
There is an urgent need to prevent food allergy and better manage its consequences. My research will identify: causes of food allergy (primary prevention); factors leading to adverse events in food allergic children (secondary prevention); and the role of food allergy in the ‘atopic march’ i.e. progression to other allergic conditions (tertiary prevention). The results of my research will be used to update policy and practice guidelines to change behaviour and improve clinical care.
Implementation Of Highly Effective Therapy For Hepatitis C
Funder
National Health and Medical Research Council
Funding Amount
$569,219.00
Summary
Hepatitis C is a major public health issue in Australia, and globally, with escalating liver disease burden. Highly effective interferon-free HCV regimens will be available from 2016 and have the potential to provide one of the greatest advances in clinical medicine in recent decades. Development of implementation strategies for new HCV therapies, particularly for highly marginalised populations including people who inject drugs and prisoners, is crucial to provide broad public health impact.
This Practitioner Fellowship will support studies that will contribute directly to the efforts to eliminate HCV infection from Australia. The research program aims to reduce transmission of HCV infection by evaluating the best models of care for i) engaging and treating high risk individuals with HCV infection, including people who inject drugs and prisoners, ii) preventing reinfection with HCV, and iii) re-treatment of individuals who fail treatment due to drug resistance.